top of page
  • Completed

NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed Myeloma

Updated: Jun 23, 2022

NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma


BCMA/CD19 Dual-Target CAR-T

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma


Sponsor:

Xijing Hospital


Gracell Biotechnology Ltd.


The study is an early, open, single-centered trial. The purpose of this study is to evaluate the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T therapy.

 

ClinicalTrials.gov Identifier: NCT04182581


Official Title: A Study of B-cell Maturation Antigen/Cluster of Differentiation Antigen 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

First Posted: December 2, 2019


Click here to see details on ClinicalTrials.gov

 

Biological: BCMA/CD19 Dual-Target CAR-T

 

Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F (Code C175471)

Autologous Anti-BCMA/CD19 Dual CAR T Cells GC012F

Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Autologous GC012F CAR-T Cells

GC 012F

GC-012F

GC012F

 
 

Location

China, Shanxi




コメント


Posts Archive
bottom of page